A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT: NCT04853251 · RECRUITING
Реклама
NCT IDNCT04853251
СтатусRECRUITING
Дата начала2021-12-14
Завершение2027-08-31
SponsorGenentech, Inc. (INDUSTRY)
First posted
Last updated
Краткое описание
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Официальный источник
Открыть на ClinicalTrials.gov →Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.